Transition From Interferon‐Based Therapy to Direct‐Acting Antivirals in Albanian Children With Chronic Hepatitis C: A 17‐Year Real‐World Experience
Advances in Virology · 2026-01 · 2026 (1)
DOI: 10.1155/av/2405090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Virology, online erschienen am 21.10.2026. Verfasst von Virtut Velmishi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Department "Mother Teresa" Hospital Tirana Albania. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Direct‐acting antivirals (DAAs) have transformed the management of chronic hepatitis C virus (HCV) infection, including in children. However, real‐world data from resource‐limited settings remain scarce.
Methods
We conducted a retrospective study of children with chronic HCV infection treated at the national pediatric hepatology center in Tirana, Albania, between 2007 and 2024. Patients were grouped according to treatment era: interferon‐based therapy or DAA regimens. Sustained virologic response (SVR), adverse events, and treatment duration were assessed.
Results
Twenty‐nine children were included (17 interferon era; 12 DAA era). SVR was achieved in 83% of patients receiving interferon‐based therapy and in all patients treated with DAAs. Adverse events were more frequent and clinically significant in the interferon group, whereas only mild events were observed in the DAA group. Treatment duration was substantially shorter with DAAs (8–12 weeks vs. 48 weeks).
Conclusions
This real‐world experience reflects the transition toward shorter, better‐tolerated, and highly effective therapies for pediatric HCV infection. While cross‐era comparisons are limited, the findings are consistent with the established efficacy of DAA regimens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Department "Mother Teresa" Hospital Tirana Albania.
- Institute of Public Health Tirana Albania cam.ac.uk.
ORCID-Profile: Virtut Velmishi, Ermira Dervishi, Gladiola Hoxha, Donjeta Bali, Enkeleda Duka, Paskal Cullufi
Zitieren
APA
Velmishi, V., Dervishi, E., Hoxha, G., Saraci, B., Bali, D., Xhafa, M., Kapllanaj, M., Duka, E., Shundi, L., & Cullufi, P. (2026). Transition From Interferon‐Based Therapy to Direct‐Acting Antivirals in Albanian Children With Chronic Hepatitis C: A 17‐Year Real‐World Experience. Advances in Virology, 2026(1). https://doi.org/10.1155/av/2405090
Vancouver
Velmishi V, Dervishi E, Hoxha G, Saraci B, Bali D, Xhafa M, et al. Transition From Interferon‐Based Therapy to Direct‐Acting Antivirals in Albanian Children With Chronic Hepatitis C: A 17‐Year Real‐World Experience. Advances in Virology. 2026;2026(1). doi:10.1155/av/2405090
BibTeX
@article{Velmishi2026,
author = {Velmishi, Virtut and Dervishi, Ermira and Hoxha, Gladiola and Saraci, Blerina and Bali, Donjeta and Xhafa, Mirela and Kapllanaj, Mirzana and Duka, Enkeleda and Shundi, Lila and Cullufi, Paskal},
title = {Transition From Interferon‐Based Therapy to Direct‐Acting Antivirals in Albanian Children With Chronic Hepatitis C: A 17‐Year Real‐World Experience},
journal = {Advances in Virology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/av/2405090}
}
EUVIMED